טוען...
Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
For metastatic soft tissue sarcoma (STS) patients not eligible for surgery, systemic treatments, including standard chemotherapy and newer biological compounds, still play the most relevant role in the management of the disease. An anthracycline and alkylating agent combination has formed the corner...
שמור ב:
| הוצא לאור ב: | BMC Med |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5455204/ https://ncbi.nlm.nih.gov/pubmed/28571564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-017-0872-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|